The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer

Nikki de Rouw, Merel de Boer, Rene J. Boosman, Michel M. van den Heuvel, David M. Burger, Joris E. Lieverse, Hieronymus J. Derijks, Geert W. J. Frederix, Rob ter Heine

Research output: Contribution to journalArticleScientificpeer-review

Fingerprint

Dive into the research topics of 'The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science